Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management

Journal of Lipids
Dhrubajyoti BandyopadhyayRaktim K Ghosh

Abstract

The risk of cardiovascular disease has been reported to have a linear relationship with LDL levels. Additionally, the currently recommended LDL target goal of 70 mg/dl does not diminish the CV risk entirely leaving behind some residual risk. Previous attempts to maximally lower the LDL levels with statin monotherapy have met dejection due to the increased side effects associated with the treatment. Nevertheless, with the new advancements in clinical medicine, it has now become possible to bring down the LDL levels to as low as 15 mg/dl using PCSK9 monoclonal antibodies alone or in combination with statins. The development of inclisiran, siRNA silencer targeting PCSK9 gene, is a one step forward in these endeavors. Moreover, various studies aiming to lower the CV risk and mortality by lowering LDL levels have demonstrated encouraging results. The current challenge is to explore this arena to redefine the target LDL levels, if required, to avoid any suboptimal treatment. After thorough literature search in the PubMed, Embase, Scopus, and Google Scholar, we present this article to provide a brief overview of the safety and efficacy of lowering LDL below the current goal.

References

Jun 3, 2004·Journal of the American College of Cardiology·James H O'KeefeRobert Vogel
Oct 18, 2005·Journal of the American College of Cardiology·Stephen D WiviottUNKNOWN PROVE IT-TIMI 22 Investigators
Mar 29, 2006·Cellular and Molecular Life Sciences : CMLS·K Pahan
Aug 1, 2007·Journal of Thrombosis and Haemostasis : JTH·B IbanezJ J Badimon
Aug 28, 2007·The American Journal of Cardiology·John C LaRosaUNKNOWN Treating to New Targets (TNT) Steering Committee and Investigators
Dec 14, 2007·Neurology·L B GoldsteinUNKNOWN SPARCL Investigators
Apr 1, 2008·The American Journal of Medicine·Igor KarpLouise Pilote
Nov 21, 2008·Journal of Lipid Research·Jay D HortonHelen H Hobbs
Nov 6, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Elizabeth A PlatzAlan R Kristal
Nov 12, 2010·Lancet·UNKNOWN Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupRory Collins
Nov 9, 2011·Nature Medicine·Christian Weber, Heidi Noels
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 3, 2012·Cholesterol·Matthias Orth, Stefano Bellosta
Jan 2, 2014·Indian Journal of Endocrinology and Metabolism·Tarun DaveVinod Somani
Aug 2, 2014·Journal of the American College of Cardiology·S Matthijs BoekholdtJohn J P Kastelein
Dec 5, 2014·PloS One·Gergana GalabovaGuenther Staffler
Nov 9, 2015·The American Journal of Cardiology·Arihiro KiyosueAtsushi Hirayama
Jan 30, 2016·Journal of the American College of Cardiology·Sabina A MurphyEugene Braunwald
Oct 16, 2016·International Journal of Clinical Practice·Terry McCormackMark Blagden
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Feb 6, 2017·Journal of the American College of Cardiology·Jennifer G RobinsonJohn J P Kastelein
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 18, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN SPIRE Cardiovascular Outcome Investigators
Mar 18, 2017·The New England Journal of Medicine·Kausik K RayJohn J P Kastelein

❮ Previous
Next ❯

Citations

May 12, 2020·Journal of Inherited Metabolic Disease·Elsa C KuijperAnnemieke Aartsma-Rus
Jun 9, 2020·Expert Opinion on Pharmacotherapy·Paramarjan Piranavan, Andras Perl
Apr 4, 2020·Postgraduate Medicine·Cezary Wójcik
May 1, 2020·European Heart Journal·Ulf LandmesserThomas F Lüscher
Apr 24, 2021·Atherosclerosis·Simon MeierJürg H Beer

❮ Previous
Next ❯

Software Mentioned

IT
SATURN
PACMAN
IMPROVE
AMI
ODYSSEY

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Giornale italiano di cardiologia : organo ufficiale della Federazione italiana di cardiologia : organo ufficiale della Società italiana di chirurgia cardiaca
Claudio CimminielloHernan Polo Friz
Revue médicale suisse
Iveta Petrova-SlaterMarco Moccetti
Expert Opinion on Biological Therapy
Giacomo PucciGiuseppe Schillaci
Expert Opinion on Biological Therapy
Marcos G ValerioWilbert S Aronow
© 2022 Meta ULC. All rights reserved